Litcius/Paper detail

Inhaled isoflurane via the anaesthetic conserving device versus propofol for sedation of invasively ventilated patients in intensive care units in Germany and Slovenia: an open-label, phase 3, randomised controlled, non-inferiority trial

Andreas Meiser, Thomas Volk, Jan Wallenborn, Ulf Guenther, Tobias Becher, Hendrik Bracht, Konrad Schwarzkopf, Rihard Knafelj, Andreas Faltlhauser, Serge C. Thal, Jens Soukup, Patrick Kellner, Matthias Drüner, Heike Vogelsang, Martin Bellgardt, Peter Sackey, Eberhard Barth, Tobias Becher, Berthold Bein, Martin Bellgardt, Paul Biever, Ralph Bogdanski, Hendrik Bracht, Sebastián Brandt, Matthias Drüner, A. Faltlhauser, Arnim Geise, Adrian‐Iustin Georgevici, Philipp Gude, Ulf Guenther, Uwe Hamsen, Christian Hönemann, Patrick Kellner, Kerstin Kellner, Azzeddine Kermad, Rihard Knafelj, Klaus Kogelmann, Rainer Kram, Andrej Markota, Werner Meermeier, Andreas Meiser, Matej Podbregar, Peter Sackey, Patrick Schramm, M. Schroeder, Konrad Schwarzkopf, Jens Soukup, Serge C. Thal, Heike Vogelsang, Thomas Volk, Jan Wallenborn, Christian Waydhas, Norbert Weiler, Richard Wetzold, Norbert Weiler, Richard Wetzold

2021The Lancet Respiratory Medicine138 citationsDOI

Topics & Concepts

MedicinePropofolSedationAnesthesiaClinical endpointIsofluraneAdverse effectIntensive care unitIntensive carePopulationRandomized controlled trialSurgeryIntensive care medicineInternal medicineEnvironmental healthIntensive Care Unit Cognitive DisordersAnesthesia and Sedative AgentsRespiratory Support and Mechanisms